Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

por Mahalingam, D, Wilding, G, Denmeade, S, Sarantopoulas, J, Cosgrove, D, Cetnar, J, Azad, N, Bruce, J, Kurman, M, Allgood, V E, Carducci, M
Publicado 2016